You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The diagnostic will be covered when patients are tested according to the Japanese Organization of Hereditary Breast and Ovarian Cancer's criteria.
Deleterious NOTCH mutations may predict more favorable immune checkpoint responses in lung cancer patients without EGFR or ALK mutations.
Women with breast cancer from Peru, Mexico, or Colombia who had greater Indigenous American ancestry were more likely to have HER2-positive tumors.
Following a positive interim analysis of the Phase III OVAL trial, Japan-based NanoCarrier plans to open trial sites for VBL Therapeutics' VB-111.
HER2-targeted bispecific antibody ZW25 will be used in combination with other drugs for HER2-positive breast cancer and gastroesophageal adenocarcinoma.
Researchers found that TP53 mutations correlated with improved disease-free survival and overall survival in pancreatic cancer patients treated with gemcitabine following surgical resection.
A study evaluated data from a Phase I/II trial of Piqray combined with an aromatase inhibitor to find mechanisms of resistance hindering clinical benefit from the therapy.
Top-line results from the first part of the Atalante 1 trial showed the company's investigational product Tedopi produced a 12-month survival rate of 46 percent.
A Phase II study suggests immune-related expression signatures and other immune markers may help find metastatic prostate cancer cases with better checkpoint blockade response.
The company announced that it is planning to submit an NDA for the drug in RET-mutant medullary thyroid cancer.